Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis

Carcinogenesis

Volumn 28, Issue 12, 2007, Pages 2657-2663

  Sanada, Masayuki ^a   Hidaka, Masumi ^b   Takagi, Yasumitsu ^a   Takano, Tomoko Y ^c   Nakatsu, Yoshimichi ^b   Tsuzuki, Teruhisa ^b   Sekiguchi, Mutsuo ^a  

^a FUKUOKA DENTAL COLLEGE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c BIOMOL ENG RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 O METHYLGUANINE; ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 1; CYCLINE; DACARBAZINE; DNA METHYLTRANSFERASE; MISMATCH REPAIR PROTEIN PMS2; NIMUSTINE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

APOPTOSIS; ARTICLE; BASE MISPAIRING; CELL ACTIVITY; CELL KILLING; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; HUMAN; HUMAN CELL; MUTATION RATE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; HUMANS; MUTATION; MUTS HOMOLOG 2 PROTEIN; NIMUSTINE; NUCLEAR PROTEINS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 36949008827     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm188     Document Type: Article

References (43)

1. Bonadonna,G. et al. (1982) Evolution in the treatment strategy of Hodgkin's disease. Adv. Cancer Res., 36, 257-293.
2. Choi,I.S. et al. (2002) Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. J. Neurooncol., 60, 171-176.
3. Eisenbrand,G. et al. (1994) DNA adducts of N-nitrosoureas. IARC Sci. Publ., 125, 277-293.
4. Gwak,H.S. et al. (2005) ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: Phase II study. J. Neurooncol., 75, 173-180.
5. Kolar,G.F. et al. (1980) 5-(3-Hydroxymethyl-3-methyl-1-triazeno) imidazole-4-carboxamide is a metabolite of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DIC, DTIC NSC-45388). Cancer Lett., 10 235-241.
6. Meer,L. et al. (1986) In vivo metabolism and reaction with DNA of the cytostatic agent, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). Biochem. Pharmacol., 35, 3243-3247.
7. Michejda,C.J. et al. (1994) DNA alkylation by triazenes and related compounds. IARC Sci. Publ., 125, 323-337.
8. Shiraishi,A. et al. (2000) Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase. Carcinogenesis, 21, 1879-1883.
9. 6-methylguanine-DNA methyltransferase. Mutat. Res., 447, 257-265.
10. Sanada,M. et al. (2004) Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent on human and mouse cells: Effects of Mgmt and Mlh1 mutations. DNA Repair (Amst.), 3, 413-420.
11. Tong,W.P. et al. (1982) Formation of the cross-link 1-[N3-deoxycytidyl),2-[N1-deoxyguanosinyl]ethane in DNA treated with N,N'-bis(2-chloroethyl)-N-nitrosourea. Cancer Res., 42, 3102-3105.
12. Takagi,Y. et al. (2003) Roles of MGMT and MLH1 proteins in alkylation-induced apoptosis and mutagenesis. DNA Repair (Amst.), 2, 1135-1146.
13. 6-methylguanine adducts. Mol. Cell, 22, 501-510.
14. Ludlum,D.B. (1990) DNA alkylation by the haloethylnitrosoureas: Nature of modifications produced and their enzymatic repair or removal. Mutat. Res., 233, 117-126.
15. Day,R.S., 3rd et al. (1980) Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature, 288, 724-727.
16. + human melanoma cells. Melanoma Res., 12, 417-427.
17. Hickman,M.J. et al. (1999) Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc. Natl Acad. Sci. USA, 96, 10764-10769.
18. 6- methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: The role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis, 12, 1857-1867.
19. Karran,P. et al. (1994) DNA damage tolerance, mismatch repair and genome instability. Bioessays, 16, 833-839.
20. 6- methylguanine DNA-methyltransferase expression. J. Pharmacol. Exp. Ther., 307, 816-823.
21. 6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J. Pharmacol. Exp. Ther., 304, 661-668.
22. - human tumor cell strains. Carcinogenesis, 4, 199-205.
23. Hidaka,M. et al. (2005) PCNA-MutSalpha-mediated binding of MutLalpha to replicative DNA with mismatched bases to induce apoptosis in human cells. Nucleic Acids Res., 33, 5703-5712.
24. Baranovskaya,S. et al. (2001) Functional significance of concomitant inactivation of hMLH1 and hMSH6 in tumor cells of the microsatellite mutator phenotype. Proc. Natl Acad. Sci. USA, 98 15107-15112.
25. Kane,M.F. et al. (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res., 57, 808-811.
26. Flohr,T. et al. (1999) Detection of mutations in the DNA polymerase delta gene of human sporadic colorectal cancers and colon cancer cell lines. Int. J. Cancer, 80, 919-929.
27. Vincent,F. et al. (1997) Mutation analysis of the transforming growth factor-beta type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-beta. Oncogene, 15, 117-122.
28. Räschle,M. et al. (1999) Identification of hMutLbeta, a heterodimer of hMLH1 and hPMS1. J. Biol. Chem., 274, 32368-32375.
29. Yao,X. et al. (1999) Different mutator phenotypes in Mlh1 - versus Pms2- deficient mice. Proc. Natl Acad. Sci. USA, 96, 6850-6855.
30. Liu,Q. et al. (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 14, 1448-1459.
31. Stojic,L. et al. (2004) Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev., 18, 1331-1344.
32. Zhou,B.B. et al. (2000) The DNA damage response: Putting checkpoints in perspective. Nature, 408, 433-439.
33. Glassner,B.J. et al. (1999) DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. Mutagenesis, 14, 339-347.
34. 6-methylguanine-DNA methyltransferase. Nucleic Acids Res., 11, 7743-7758.
35. Kawate,H. et al. (2000) A defect in a single allele of the Mlh1 gene causes dissociation of the killing and tumorigenic actions of an alkylating carcinogen in methyltransferase-deficient mice. Carcinogenesis, 21, 301-305.
36. Jiricny,J. (1998) Eukaryotic mismatch repair: An update. Mutat. Res. 409, 107-121.
37. Kolodner,R.D. et al. (1999) Eukaryotic DNA mismatch repair. Curr. Opin. Genet. Dev., 9, 89-96.
38. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl Acad. Sci. USA, 93, 6443-6447.
39. Caporali,S. et al. (2004) DNA damage induced by temozolomide signals to both ATM and ATR: Role of the mismatch repair system. Mol. Pharmacol., 66, 478-491.
40. Ochs,K. et al. (2000) Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res., 60, 5815-5824.
41. Matsukura,S. et al. (2003) Combined loss of expression of O6-methylguanine-DNA methyltransferase and hMLH1 accelerates progression of hepatocellular carcinoma. J. Surg. Oncol., 82, 194-200.
42. Liu,L. et al. (2003) Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts. Mol. Cancer Ther., 2, 1061-1066.
43. Trivedi,R.N. et al. (2005) The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res., 65, 6394-6400.